John G. Groskoph

Pfizer
Executive Director, Global CMC
John Groskoph leads the New Products CMC function at Pfizer and has over 20 years of pharmaceutical industry experience. John has worked in a variety of regulatory, quality and production assignments and brings experience in Quality & Compliance Systems, clinical trial submissions through post-approval change management. John has a particular focus on bringing new technologies and new approaches through the CMC regulatory approval process. John holds a B.S. in Electrical Engineering from Lafayette College, Pennsylvania and an M.B.A. from Columbia University, New York, USA.


Related Articles

Risk Management for Avoidance of Drug Shortages
Features
Risk Management for Avoidance of Drug Shortages

Shortages of essential medicines around the world have been an ongoing concern for patients, caregivers, and regulators and have been exacerbated by the COVID-19 pandemic. Many regulators have instituted requirements for reporting potential or actual drug shortages.1

  • 1Acosta, A., E. P. Vanegas, J. Ronvira, B. Godman, and T. Bochenek. “Medicine Shortages: Gaps Between Countries and...